• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can Regencell Bioscience Holdings (RGC) Justify Its Valuation On A Wider Full Year Loss?

    Simply Wall St·10/08/2026 11:43:19
    语音播报

    Regencell Bioscience Holdings earnings jolt investor focus

    Regencell Bioscience Holdings (RGC) has reported full-year results to June 30, 2026, showing a net loss of US$11.7 million, compared with US$3.58 million a year earlier.

    Regencell Bioscience Holdings shares now trade at US$7.11, with a 7 day share price return of 14.31% and a 90 day move of 17.13%. However, the year to date share price return has declined 65.38% and the 1 year total shareholder return has fallen 63.35%, despite a very large 5 year total shareholder return that points to earlier, outsized gains.

    Scan beyond Regencell Bioscience Holdings and compare this kind of high-volatility story with our hand picked 12 elite penny stocks with strong financials that combine small size with meaningful trading action.

    After a sharp 7 day rebound and a much weaker full year result, the real question for Regencell Bioscience Holdings is where fair value falls between recent trading levels and any valuation range investors are using next.

    Preferred price-to-book multiple of 2,889x for Regencell Bioscience Holdings: Is it justified?

    On the latest figures, Regencell Bioscience Holdings trades at a P/B ratio of 2,889x, which sits alongside a share price of $7.11 that has swung sharply over recent months. That combination of a very high multiple and heavy volatility gives investors plenty to interrogate before leaning on the latest rebound.

    The price to book ratio compares a company’s market value to its net assets, so it often matters most for asset backed businesses or those with consistent profitability. Regencell Bioscience Holdings currently reports no revenue, ongoing losses and a very weak return on equity, which means the valuation rests more on expectations than on current financial performance.

    RGC is considered expensive on this measure when lined up against both its direct peers and the wider pharmaceuticals group. The stock trades at a P/B of 2,889x versus a peer average of 8.4x and an industry level of 2x, so the market is assigning a very large premium that is difficult to reconcile with an unprofitable profile and declining earnings over the past five years.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 2,889x (OVERVALUED)

    Still, the story around Regencell Bioscience Holdings can shift quickly if funding access tightens, or if clinical and commercial execution on its TCM pipeline disappoints.

    Find out about the key risks to this Regencell Bioscience Holdings narrative.

    Next Steps

    Worried this all sounds one sided on Regencell Bioscience Holdings and want your own read on the situation before sentiment shifts again? Take a few minutes to review the underlying data and stress test your thesis against the 3 important warning signs.

    Looking for more investment ideas beyond Regencell Bioscience Holdings?

    Do not stop at Regencell Bioscience Holdings when there are other opportunities worth putting on your radar, especially with tools built to surface clear, data backed ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.